| UHC Commercial Medical & Drug | Gazyva® (Obinutuzumab) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Gene Therapies for Hemophilia B – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Home Hemodialysis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Hysterectomy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Implanted Electrical Stimulator for the Spinal Cord – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Injectable Dermal Fillers and Bulking Agents – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Interspinous Fusion and Decompression Devices – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Ketalar® (Ketamine) and Spravato® (Esketamine) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Light and Laser Therapy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Liposuction for Lipedema – Commercial and Individual Exchange Medical Policy | 2026-01-01 |